Not sure what others think and while I would personally love a dividend I think the likelihood is NEU will preserve the cash holdings outside of the current buyback amount and leave it both as a moat and gathering interest for a rainy day. Couple of assumptions in my earlier musings ($500 million US reached in 2026 and EU approval) without taking into account cost blowouts for the various trials. Acadia allegedly spent near $300 million on trofinetide phase 3 although this was reputedly due in large part to manufacturing costs of the drug which I understand is not an issue for 2591. I suppose the last thing we want to be doing is needing to raise capital leading into a big phase 3 result although I agree this appears highly unlikely.
Who knows - iif share price appreciates from here we may also have seen the last of the buyback!
NEU Price at posting:
$13.20 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)